Evident Move Towards Fewer Platforms from Large Number of Platforms Per Company in Biopharmaceutical Contract Manufacturing
Increased Acquisitions, Move to Full Service Providers, and Attaining Cost Efficiency are Factors Being Considered by Biopharmaceutical Contract Manufacturing Companies, Finds a New Study from FMI
View full press release